Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

Daiichi Sankyo's head of global R&D, Ken Takeshita, said that EGFR-mutated NSCLC is known to be difficult to treat in the second-line metastatic setting, but added that the company is "conducting ...

postponing the time until additional treatment may be needed," commented Ken Takeshita, Daiichi Sankyo's global R&D chief. Safety data from the new study will be closely watched, as Enhertu has ...

The much-anticipated series, which has been in production for eight years, was directed and produced by Ken Burns, Sarah Botstein and David Schmidt and written by long-time collaborator Geoffrey C.

1 Day DSKYF 13.47% DJIA -0.22% S&P 500 0.01% Health Care/Life Sciences 0.16% ...